Scarica l'app Stockscreener
78.47
2.63%
2.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$76.46
Aprire:
$76.54
Volume 24 ore:
1.33M
Relative Volume:
1.11
Capitalizzazione di mercato:
$6.30B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-13.21
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+4.21%
1M Prestazione:
+16.82%
6M Prestazione:
+69.81%
1 anno Prestazione:
+82.96%
Intervallo 1D:
$75.34
$79.98
Intervallo di 1 settimana:
$74.02
$79.98
Portata 52W:
$35.95
$79.98
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
78.47 | 6.14B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Neo Ivy Capital Management Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
4,537 Shares in PTC Therapeutics, Inc. $PTCT Bought by CFC Planning Co LLC - MarketBeat
Ptc Therapeutics stock hits all-time high at 78.75 USD By Investing.com - Investing.com Nigeria
Ptc Therapeutics stock hits all-time high at 78.75 USD - Investing.com India
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares - MarketBeat
Leerink Partnrs Has Negative Outlook of PTCT FY2026 Earnings - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) sets Dec. 2 R&D Day in New York, pipeline updates - Stock Titan
Why PTC Therapeutics Inc. (BH3) stock is a must watch tickerJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Published on: 2025-11-20 03:07:50 - newser.com
What downside risks could hit PTC Therapeutics Inc. (BH3) stockJuly 2025 Reactions & Capital Efficient Trading Techniques - newser.com
PTC Therapeutics Inc. (PTCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will PTC Therapeutics Inc. (BH3) stock benefit from mergersProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Duchenne Muscular Dystrophy Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Santhera Pharmaceuticals - Barchart.com
PTC Therapeutics Executive Sells Shares - TradingView
VP Boulding Sells 2,812 ($213.7K) Of PTC Therapeutics Inc [PTCT] - TradingView
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Can PTC Therapeutics Inc. stock reach $100 price targetJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
PTC Therapeutics stock rating reiterated by Cantor Fitzgerald at Overweight - Investing.com Canada
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividends2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
Rockefeller Capital Management L.P. Buys 7,751 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Bank of New York Mellon Corp Acquires 49,728 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
(PTCT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
PTC Therapeutics (NASDAQ:PTCT) Nasdaq Composite Shows Trial Motion - Kalkine Media
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
PTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week HighHere's Why - MarketBeat
Is PTC Therapeutics Inc. stock a top pick in earnings season2025 Price Momentum & High Return Stock Watch Alerts - newser.com
Savant Capital LLC Sells 5,487 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Jefferies: Strategic Moves in Rare Disease By Investing.com - Investing.com Canada
Can PTC Therapeutics Inc. stock sustain revenue growthEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
VP Boulding Files To Sell 2,812 Of PTC Therapeutics Inc [PTCT] - TradingView
9,941 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Vise Technologies Inc. - MarketBeat
Emma Reeve Sells 7,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (PTCT) Price Target Increased by 15.54% to 80.45 - Nasdaq
PTC Therapeutics, Inc. $PTCT Shares Sold by Candriam S.C.A. - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.IPO Watch & Community Driven Trade Alerts - newser.com
Campbell & CO Investment Adviser LLC Acquires Shares of 14,893 PTC Therapeutics, Inc. $PTCT - MarketBeat
Aviva PLC Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-16 01:11:13 - newser.com
How PTC Therapeutics Inc. stock compares to growth peersWeekly Investment Report & Weekly Stock Performance Updates - newser.com
Jupiter Asset Management Ltd. Invests $2.25 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investors2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Ptc Therapeutics stock hits 52-week high at 76.11 USD By Investing.com - Investing.com Canada
PTC Therapeutics Director Emma Reeve Sells 7,333 Shares - TradingView
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):